SUMMARY
Cyclop MedTech plans to use the funds to scale up its product installations in Tiers 2 and 3 cities
It is currently working on building three more products in the neuro-vestibular space
It will also focus on capturing other Asian markets with a target of 1K installations in the next five years
Cyclops MedTech, a startup working on clinical and wearable diagnostic and rehab products for neuro-vestibular disorders using eye-tracking technology, has raised $1 Mn from Bengaluru-based marquee venture capital (VC) firm Unitus Ventures. Existing investor C P Bothra, the Chief Operating Officer and Managing Director of Medreich India, also participated in the round.
The Bengaluru-based startup plans to use the recently raised funds to augment its role as a leader in the neuro-vestibular diagnostic space and rapidly scale up its installations base in India and the rest of Asia.
Cyclops Medtech was founded by Niranjan Subbarao, Srinivas Dorasala, and Ravi Nayar in 2015. The platform captures, measures, and analyses manifestations of neuro-vestibular disorders, helping clinicians determine their root cause in order to plan appropriate early-stage treatment.
The startup has a team of doctors, engineers, and business professionals. It won the coveted NASSCOM Emerge 50 — League of 10 Award in 2017.
One of Cyclops’ flagship products is BalanceEye, a balance assessment solution for diagnosing vertigo and balance disorders, and claims to have nearly 100 installations of the device.
Its future plans include scaling up BalanceEye installations across India, primarily in Tier 2 and Tier 3 cities. Further, the startup will also focus on capturing other markets in Asia with a target of 1K installations over the next five years. It is currently also working on three other products in the neuro-vestibular space.
“We intend to use funds from this round to further augment our leadership position by rapidly increasing the installation as well as subscription base in India as well as few other emerging markets. By achieving the milestone of 100 installations, we already have the highest base in India. We would also fast-track development of our stroke screening product and launch it next year,” Subbarao said in a statement.
According to a January 2018 report by RedSeer, the Indian market diagnostics services has been growing over the past couple of years at a rate of 15%-20% and stood at nearly $5.82 Bn (INR 40,000 Cr) as of 2016.
As per a June 2018 report by the IBEF, the Indian healthcare industry is expected to grow at a CAGR of 16.28 % during 2008-22. It was predicted to touch $106 Bn in 2017 and $372 Bn by 2020.
The Indian healthtech space is currently dominated by players such as MedPlus, 1mg, NetMeds, Punit Soni’s Suki, Visit, Innovaccer, Zoctr, Lybrate, and Tricog, among others.
